ALK POSITIVE MALIGNANCIES

Clinical trials for ALK POSITIVE MALIGNANCIES explained in plain language.

Never miss a new study

Get alerted when new ALK POSITIVE MALIGNANCIES trials appear

Sign up with your email to follow new studies for ALK POSITIVE MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Lifeline extended: cancer drug access continues for responding patients

Disease control Ongoing

This study allows patients with ALK-positive cancers who are already taking ceritinib in a Novartis trial to continue receiving the drug if their doctor believes they're benefiting from it. It primarily monitors the drug's safety and side effects in these patients over the long t…

Matched conditions: ALK POSITIVE MALIGNANCIES

Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

ALK POSITIVE MALIGNANCIES

Get alerted when new ALK POSITIVE MALIGNANCIES trials appear

Lifeline extended: cancer drug access continues for responding patients